Nexalin Technology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY Revenue (est.)
$345Knext fiscal year
FY EPS (est.)
-$0.38next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release (Form 10-Q) | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Pivotal Insomnia Trial Enrollment Quarterly0.0Target: 160 participants
Quarterly Revenue Quarterly15KTarget: Commercial scale-up post-FDA clearance
Cash and Short-Term Investments Quarterly2.7MTarget: Sufficient capital to fund pivotal trials and operations
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days before the regulatory deadline (July 20, 2026), or execute a reverse stock split.
- Going Concern StatusTrigger: Auditor's substantial doubt regarding ability to continue as a going concernAction: Secure additional equity financing through the at-the-market (ATM) program or strategic partnerships to extend the cash runway.
- FDA De Novo Regulatory Pathway for HALO ClarityTrigger: Completion of the 160-participant pivotal insomnia trialAction: Compile clinical data and submit a De Novo Classification Request to the FDA to establish a new product category.
Research as of 20 Jun 2026